Visceral or central obesity characterized by excess body adipose tissue represents the main aspect of the metabolic syndrome (MS), defined by a set of cardiovascular risk factors, usually related to central fat deposition and insulin resistance. Generally, the clinical treatment of obesity and MS leads to a weight loss considered, but not sustained in most patients, requiring the indication of bariatric surgery. The main objective of this study was to investigate the behavior of the inflammatory markers
\nadiponectin, resistin, leptin, TNF-alpha, interleukins IL1-beta, IL-6, IL-8, IL-17, Il-23 and IGF-1 in patients, women with severe obesity and MS undergoing Roux-en-Y gastric bypass surgery. This is a randomized controlled clinical trial involving female patients with a clinical diagnosis of severe obesity and MS with indication for bariatric surgery, recruited from the Obesity Surgery Outpatient Clinic of the Irmandade da Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo from January to December 2019. Initially, 216 patients were invited and 134 were eligible. The patients involved in this study were divided into a control group (CG n=11) not undergoing bariatric surgery and bariatric surgery group (GCB n=21). Anthropometric, demographic and clinical characteristics were collected from all patients. Blood samples were collected before and after 6 months of bariatric surgery to evaluate biochemical parameters (lipid profile and blood glucose), in addition to the inflammatory profile. The results showed that GCB showed significant reductions in weight, BMI, total cholesterol, LDL, triglycerides, glucose, leptin, resistin, TNF-\u03b1, IL-1 , IL-6 and IL-17, in contrast to increased levels of HDL and adiponectin after surgery when compared to data obtained both pre-surgery and in the CG group. With this study, it can be concluded that weight reduction induced by bariatric surgery by GVYB was able to significantly improve plasma biochemical parameters (lipid profile and blood glucose) as well as the systemic inflammatory status of severely obese patients with MS.<\/p>\n